Intralytix, Inc. is a biotechnology company focused on the discovery, production and marketing of bacteriophage-based products to control bacterial pathogens in environmental, food processing, and medical settings.
Bacteriophages (bacteria-eater: from the Greek phago meaning "to eat" or "to develop at the expense of") are the most abundant microorganisms on earth. They are the natural enemies of bacteria. Lytic bacteriophages can very effectively kill their targeted specific bacteria without affecting anything else, ensuring an unprecedented level of safety for an antimicrobial.
In The News
Intralytix receives a positive #LuxTake by Lux Research
Intralytix was given "Positive" Lux Take by Lux Research in its report to its subscribing membership.
Antibiotic-resistant 'superbugs' could be the next big health threat. Beneficial viruses could be the solution
Maryland is a hotspot for research and production of superbug-killing bacteriophages.
Phage Against the Machine
If you thought food poisoning was just a matter of the occasional stomach upset from a dodgy shrimp or two, the CDC has some unsettling numbers for you.
Intralytix awarded patent by USPTO for novel Shigella bacteriophages and their uses
Intralytix, Inc. announced today that it has been issued a patent by the U.S. Patent & Trademark Office (USPTO) covering its Shigella bacteriophages and their various applications.